Previous 10 | Next 10 |
Sesen Bio (SESN) announces that it had a positive Application Orientation Meeting ((AOM)) with the FDA regarding its Biologic License Application ((BLA)) for Vicineum, for the treatment of BCG-unresponsive non-muscle invasive bladder cancer ((NMIBC)).The objectives of an AOM include familiari...
Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported that on January 29, 2021 the Company participated in a productive Application Orientation Meeting with the FDA regarding ...
Shares of Sesen Bio (NASDAQ: SESN) were soaring 10.9% higher as of 11:26 a.m. after rising as much as 19.4% earlier in the day. The big jump came after Canaccord analyst John Newman called Sesen "a must-own small-cap stock for 2021." Should investors buy this biotech stock b...
Caladrius Biosciences (CLBS) +120%.Aptorum Group (APM) +61% as Canada approves early-stage infection drug trial.Steel Connect (STCN) +54%.Dare Bioscience (DARE) +39%.ENDRA Life Sciences (NDRA) +36%.Lineage Cell Therapeutics (LCTX) +34%.Inuvo (INUV) +33%.eMagin Corporation (EMAN) +28...
Sesen Bio ([[SESN]] -1.3%) announces Assessment Aid submission to the FDA in relation to its marketing application for its bladder cancer treatment Vicineum in a bid to reduce the review time taken by the agency.The Assessment Aid is based on the FDA Multidisciplinary Review template with the...
National Medical Products Administration in China has accepted for review the Investigational New Drug ((IND)) submitted by Sesen Bio's ([[SESN]] -4.7%) partner Qilu Pharmaceutical, to start proposed clinical trial to evaluate Vicineum in Greater China, in patients with no...
Clinical trial expected to be initiated shortly after NMPA approval of the IND Sesen Bio to receive $3M milestone payment upon IND approval Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment o...
3 Penny Stocks To Watch Gaining Interest From Biotech Traders As 2021 gets off to a wild start for the market, penny stocks have become a clear focus. Much of the momentum driving these stems from larger trends in the overall market. For instance, we saw today the riots in the Capit...
Hot Penny Stocks For your Year-End Watch List Are you ringing in the New Year with penny stocks ? If you haven’t any cheap stocks on your watch list yet, you might want to take a second look. This week has been red hot for stocks under $5 and no, it isn’t because o...
Sesen Bio ([[SESN]] -19.3%) has submitted marketing application to the FDA seeking approval for Vicineum, its lead candidate, for the treatment of high-risk, BCG-unresponsive non-muscle invasive bladder cancer.Within 60 days after receipt of the completed application, the FDA w...
News, Short Squeeze, Breakout and More Instantly...
Sesen Bio Inc. Company Name:
SESN Stock Symbol:
NASDAQ Market:
Declares Special Dividend in the Aggregate of $75 Million Approximately 88% Voted in Favor of the Merger at the Special Meeting Merger on Track to Close on March 7, 2023 Sesen Bio, Inc. (Nasdaq: SESN) (“Sesen Bio” or the “Company”), today anno...
Sesen Bio Board Believes the Pending Merger with Carisma is the Most Value-Maximizing Option for Stockholders Reiterates Support from Several of Sesen Bio’s Largest Stockholders and Two Leading Independent Proxy Advisors Sesen Bio Board Unanimously Recommends All St...
Positive Recommendations Underscore that Carisma Merger Maximizes Value for Sesen Bio Stockholders Sesen Bio Board Unanimously Recommends All Stockholders to Follow ISS and Glass Lewis’s Recommendations to Vote “FOR” Value Maximizing Merger on WHITE ...